B2M is overexpressed in gliomas, correlates with tumor grade, immune infiltration, and mesenchymal subtype; lower expression predicts longer survival, highlighting B2M as a prognostic biomarker and potential therapeutic target [53,54]. Here, B2M is linked to neoplasm.